Drug
Dosing Interruption OF Natalizumab
Dosing Interruption OF Natalizumab: highest development phase Post-Market, developed by Biogen. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Biogen
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dosing Interruption of Natalizumab NCT04048577 | Post-Market | Multiple Sclerosis |
Latest
No recent events.
Follow Dosing Interruption OF Natalizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.